About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7434 record(s)
Req # A-2023-00109
Epicurus Capital Inc. (the “Purchaser”) purchase from [Name Removed] (the “Vendor”) PT LT 63 PL BR 4 BRAMPTON S OF NELSON ST AKA BLK 4 AS IN RO1048343 ; BRAMPTON; being all of PIN 14108 0166 (LT) 17 Mill Street North, Brampton, Ontario, L6X 1S5 (the “Property”) Closing Date: As soon as possible Our File No.: 9056-180Organization: Canadian Nuclear Safety Commission
March 2024
Req # A-2023-00110
Epicurus Capital Inc. (the “Purchaser”) purchase from [Name Removed] (the “Vendor”) PT LT 64 BLK 4 PL BR 4 BRAMPTON S/S OF NELSON ST; PT LT 65 BLK 4 PL BR 4 BRAMPTON S/S OF NELSON ST AS IN RO974766 ; BRAMPTON ; SUBJECT TO EXECUTION96-05252, IF ENFORCEABLE. ; SUBJECT TO EXECUTION 96-05499, IF ENFORCEABLE.; being all of PIN 14108-0164 (LT) 21 Mill Street North, Brampton, Ontario L6X 1S5 (the “Property”) Closing Date: As soon as possible Our File No.: 9056-188Organization: Canadian Nuclear Safety Commission
March 2024
Req # A-2023-00117
Epicurus Capital Inc. (the “Purchaser”) purchase from [Names removed] (collectively, the “Vendor”) PT LT 63 BLK 4 PL BR4 BRAMPTON S/S OF NELSON ST PT 1, 43R17255 ; BRAMPTON; being all of PIN 14108-0165 (LT) 19 Mill Street North, Brampton, Ontario L6X 1S5 (the “Property”) Closing Date: As soon as possible Our File No.: 9056-194Organization: Canadian Nuclear Safety Commission
March 2024
Req # A-2023-00118
Please provide copies of the following briefing notes, providing interim disclosure as each is finalized for release: * 7025252 — Recommendation to withdraw from Sustainable Network for Independent Technical EXpertise on radioactive waste management (SITEX_Network) * 7160478 — CNSC Readiness to Regulate Enabling the deployment of safe nuclear projects * 7176466 — Options for Efficiencies in Reviewing Proposed Nuclear Projects * 7208799 — Future-Oriented Statement of OperationsOrganization: Canadian Nuclear Safety Commission
March 2024
Req # A-2023-00121
The minutes of the CNSC’s Management Committee for February 2024.Organization: Canadian Nuclear Safety Commission
March 2024
Req # A-2016-000420
Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings between Celltrion (health care company) and Health Canada between September 1, 2014 and June 30, 2015.Organization: Health Canada
March 2024
Req # A-2019-001464
All domestic Adverse Drug Reaction (ADR) reports for Tetanus, Diphtheria and Pertussis (Tdap) Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Polio Vaccine (IPV), Diphtheria, Tetanus and Pertussis (DTaP), Flu for the period of October 1, 2018 - end of March 2019.Organization: Health Canada
March 2024
Req # A-2019-001525
The Clinical Overview, Clinical Summary of Efficacy and Clinical Summary of Safety submitted to Health Canada as part of the Supplemental New Drug Submission (SNDS) (control number: 204690; decision date: 2018-03-29) in respect of TALTZ.Organization: Health Canada
March 2024
Req # A-2020-001374
For the period 2015 to April 19, 2021, and in relation to natural health product brand names containing the phrase “glucosamine sulfate” or “glucosamine sulphate”, with license holders named WN Pharmaceuticals Ltd, Natural Factors Nutritional Products Limited, or Jamieson Laboratories Inc., the following documents. All product licences, and the specifications to which the natural health product will comply. All applications for a product licence, correspondences with respect to those applications, and the attestations by the applicants that the product will be manufactured and distributed in accordance with good manufacturing practices. All testing done of the product, and correspondences made in relation to the testing of the product. All correspondences between the Minister and a licensee, manufacturer, importer or distributer to stop their sale of the product. All correspondences in relation to labelling and packaging of the product; and all complaints of non-compliance in respect of the product. For the period May 6, 2004 to April 19, 2021, all monographs of “glucosamine sulfate” and “glucosamine hydrochloride”Organization: Health Canada
March 2024
Req # A-2021-001830
A summary of the costs incurred to develop, advertise, and run the COVID Alert App program mentioned in this news story: https://globalnews.ca/news/8478550/attempts-improve-covid-alert-stall-lack-of-interest-provinces/. Records from the start of the program to January 21, 2022.Organization: Health Canada
March 2024